Spliceor

Spliceor, a University of Cambridge spinout, has developed a novel, patented cancer gene therapy platform to progress curative treatments for the most aggressive cancers that respond poorly to alternative treatments. We have identified a highly accessible and widely expressed cancer cell target for our disruptive cancer-selective therapies. Liver and pancreatic cancers are the initial indications, but the approach is applicable to many other malignancies. Our mission is to provide curative and easily tolerated gene therapies to cancer patients.